



Published in final edited form as:

J Alcohol Drug Depend. 2015 October ; 3(5): . doi:10.4172/2329-6488.1000e127.

Preclinical Efficacy of Novel Vesicular Monoamine Transporter 2 Inhibitors as Antagonists of d-Methamphetamine Self-Administration in Rats

Takato Hiranita*

Division of Neurotoxicology, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration (FDA), 3900 NCTR Road, Jefferson, AR 72079-9501, USA

Editorial

A series of studies by Drs. Linda Dvoskin and Michael Bardo demonstrated the preclinical efficacy of novel vesicular monoamine transporter 2 (VMAT2) inhibitors as antagonists of d-methamphetamine self-administration in rats [1-6]. This is an important finding since there is a lack of FDA-approved medications to treat amphetamine-type stimulant abuse. There are also few if any candidate compounds that show preclinical efficacy as amphetamine antagonists (e.g. [7]).

Reinforcing effects of stimulants result from their common capacity to increase extracellular dopamine (DA) levels in terminal regions of mesolimbic dopaminergic neurons [8]. Amphetamines are substrates for the dopamine transporter (DAT), while cocaine inhibits DA uptake and functions as a DAT inhibitor [8]. Thus stimulants function as indirect DA agonists. In addition to the DAT, uptake of amphetamines into cytoplasm via DAT results in DA release into synaptic clefts through actions at the cytoplasmic vesicular monoamine transporter 2 (VMAT2) in the brain [8]. Thus VMAT2 is a potential target of action for amphetamines. Consistent with this hypothesis, Drs. Dvoskin and Bardo demonstrated that novel VMAT2 inhibitors can decrease d-methamphetamine self-administration in rats [1-6]. Importantly, the d-methamphetamine-antagonist effects of VMAT2 inhibitors were specific for the reinforcing effects of d-methamphetamine. For example, a VMAT2 inhibitor N-(1,2R-dihydroxypropyl)-2,6-cis-di-(4-methoxyphenethyl)piperidine hydrochloride (GZ-793A) was more potent in decreasing self-administration responding for d-methamphetamine than in decreasing that of cocaine [5] or food-reinforced responding [5,6]. The pharmacological specificity relative to food-reinforced responding was demonstrated with other novel VMAT2 inhibitors lobelane [4], meso-transdiene [3], and cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride (UKCP-110) [1]. In addition, another group previously demonstrated a lack of effect for the prototype VMAT2 inhibitor reserpine on cocaine self-administration using rhesus monkeys [9]. In contrast, the prototype VMAT2 inhibitor (\pm)-

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Corresponding author: Takato Hiranita, Division of Neurotoxicology, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration (FDA), 3900 NCTR Road, Jefferson, AR 72079-9501, USA, Tel: +61-3-9214-5596, +61-3-5327-6335, takato.hiranita@fda.hhs.gov.

tetrabenazine failed to exhibit pharmacological specificity. (\pm)-Tetrabenazine was equipotent in decreasing self-administration responding for d-methamphetamine and food reinforced responding [2].

The novel VMAT2 inhibitors possess a clinically preferential profile since the duration of action as d-methamphetamine antagonists in vivo lasted at least 60 minutes [1-6], which is approximately 12-fold longer than the elimination half-life of the prototype VMAT2 inhibitor (\pm)-tetrabenazine [10]. However, the novel VMAT2 inhibitors need improvement to be useful clinically since they possess relatively low affinity for VMAT2 (K_i values $>2,000$ nM, see Table 1). VMAT2 is a cytoplasmic protein and VMAT2 inhibitors need to penetrate plasma membranes in vivo.

Despite the fact that the novel VMAT2 inhibitors exhibited low affinities for VMAT2, the series of studies by Drs. Dwoskin and Bardo demonstrated the preclinical efficacy of a novel class of antagonists for d-methamphetamine self-administration. Although it is still relatively unknown how amphetamines increase DA levels in synaptic clefts, these findings suggest that development of VMAT2 inhibitors as a specific amphetamine antagonists in vivo is possible.

Acknowledgments

The present work was supported by the Division of Neurotoxicology/NCTR/U.S. FDA. The information in the present article is not a formal dissemination of information by the FDA and does not represent agency position or policy.

References

1. Beckmann JS. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. *J Pharmacol Exp Ther.* 2010; 335:841–851. [PubMed: 20805303]
2. Meyer AC. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: Locomotor activity, drug discrimination and self-administration. *Neuropharmacology.* 2011; 61:849–856. [PubMed: 21669212]
3. Horton DB, Siripurapu KB, Norrholm SD, Culver JP, Hojamat M, et al. Meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. *J Pharmacol Exp Ther.* 2011; 336:940–951. [PubMed: 21177475]
4. Neugebauer NM, Harrod SB, Stairs DJ, Crooks PA, Dwoskin LP, et al. Lobelane decreases methamphetamine self-administration in rats. *Eur J Pharmacol.* 2007; 571:33–38. [PubMed: 17612524]
5. Beckmann JS, Denehy ED, Zheng G, Crooks PA, Dwoskin LP, et al. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. *Psychopharmacology (Berl).* 2012; 220:395–403. [PubMed: 21938414]
6. Wilmouth CE, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. *Pharmacol Biochem Behav.* 2013; 112:29–33. [PubMed: 24075974]
7. Hiranita T, Kohut SJ, Soto PL, Tanda G, Kopajtic TA, et al. Preclinical efficacy of N-substituted benzotropine analogs as antagonists of methamphetamine self-administration in rats. *J Pharmacol Exp Ther.* 2014; 348:174–191. [PubMed: 24194527]
8. Fasano A, Bentivoglio AR. Tetrabenazine. *Expert Opin Pharmacother.* 2009; 10:2883–2896. [PubMed: 19929707]

9. Wilson MC, Schuster CR. Aminergic influences on intravenous cocaine self-administration by Rhesus monkeys. *Pharmacol Biochem Behav.* 1974; 2:563–571. [PubMed: 4431820]
10. DaSilva JN, Kilbourn MR. In vivo binding of [¹¹C]tetrabenazine to vesicular monoamine transporters in mouse brain. *Life Sci.* 1992; 51:593–600. [PubMed: 1640810]
11. Nickell JR, Siripurapu KB, Vartak A, Crooks PA, Dwoskin LP. The vesicular monoamine transporter-2: An important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. *Adv Pharmacol.* 2014; 69:71–106. [PubMed: 24484975]
12. Horton DB, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP. Novel N-, 2-dihydroxypropyl analogs of lobeline inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. *J Pharmacol Exp Ther.* 2011; 339:286–297. [PubMed: 21778282]
13. Nickell JR, Krishnamurthy S, Norrholm S, Deaciuc G, Siripurapu KB, et al. Lobeline inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. *J Pharmacol Exp Ther.* 2010; 332:612–621. [PubMed: 19855096]
14. Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA. Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. *J Med Chem.* 2005; 48:5551–5560. [PubMed: 16107155]
15. Schwartz K, Weizman A, Rehavi M. The effect of psychostimulants on [³H] dopamine uptake and release in rat brain synaptic vesicles. *J Neural Transm (Vienna).* 2006; 113:1347–1352. [PubMed: 16362637]
16. Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, et al. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. *J Pharmacol Exp Ther.* 2006; 319:237–246. [PubMed: 16835371]

Table 1Inhibition by various compounds of specific binding to the VMAT2 (K_i Value, nM).

| Compound | VMAT2 ($[^3\text{H}]$ dihydrotetrazenazine binding) |
|---------------------------|--|
| (\pm)-Tetrabenazine | 13 (\pm 1) [11] |
| GZ-793A | 8,290 (\pm 2,790) [12] |
| Lobeline | 2,040 (\pm 640) [13] 970 (\pm 190) [1] |
| Meso-Transdiene | 9,880 (\pm 2,220) [14] |
| UKCP-110 | 2,660 (\pm 366) [1] |
| <i>d</i> -Methamphetamine | 80,100 (\pm 19,500) [13] No inhibition at 100 μM [15] |
| <i>d</i> -Amphetamine | No inhibition at 100 μM [15] |
| Cocaine | No inhibition at 100 μM [16] |

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript